Phthalazine Derivatives as VEGFR‐2 Inhibitors: Docking, ADMET, Synthesis, Design, Anticancer Evaluations, and Apoptosis Inducers
Drug Development Research · 2025
DOI: 10.1002/ddr.70037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Hatem Hussein Bayoumi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt. Hauptthemen laut MEDLINE: Phthalazines, Vascular Endothelial Growth Factor Receptor-2, Apoptosis, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
New phthalazine‐derived inhibitors for VEGFR‐2 were synthesized for anticancer evaluations. Also, docking studies were performed to explore the suggested binding orientations of the novel derivatives inside the binding site of VEGFR‐2. The achieved biological data were extremely interrelated to that of docking study. In specific, derivative 3f was the greatest effective compound against HepG2 and MCF‐7 cancer cell lines with IC 50 = 0.17 ± 0.01 and 0.08 ± 0.01 µM individually. The six highly active derivatives 3b, 3e, 3f, 3g, 6a, and 6b were estimated for their VEGFR‐2 inhibitory effects. Derivative 3f was the greatest effective compound which inhibited VEGFR‐2 at IC 50 = 0.0557 ± 0.002 µM. The activities of 3f were assessed against MCF‐7 cancer cells for apoptosis induction, cell cycle distribution, and growth inhibition. Compound 3f induced early apoptosis (21.44%) by more than 36 folds over the control (0.59%). The obtained results showed that compound 3f induced necrotic effect (6.03%) by more than threefolds over the control (1.75%). On the other hand, compound 3f improved the level of the pro‐apoptotic protein; Bax by approximately fivefolds. Moreover, compound 3f noticeably decreased the levels of the anti‐apoptotic proteins Bcl‐2 by nearly fourfolds in comparison to the control. In addition, derivative 3f remarkably enhanced the Bax/Bcl2 ratio by nearly 18 folds, as compared to the control. Finally, our derivatives 3f, 3g, and 6b revealed good in silico considered ADMET profile in comparing to sorafenib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt.
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt.
ORCID-Profile: Hatem Hussein Bayoumi, Mohammed A Dahab, Khaled El-Adl
Zitieren
APA
Bayoumi, H. H., Ibrahim, M. K., Dahab, M. A., Khedr, F., & El-Adl, K. (2025). Phthalazine Derivatives as VEGFR‐2 Inhibitors: Docking, ADMET, Synthesis, Design, Anticancer Evaluations, and Apoptosis Inducers. Drug Development Research. https://doi.org/10.1002/ddr.70037
Vancouver
Bayoumi HH, Ibrahim MK, Dahab MA, Khedr F, El-Adl K. Phthalazine Derivatives as VEGFR‐2 Inhibitors: Docking, ADMET, Synthesis, Design, Anticancer Evaluations, and Apoptosis Inducers. Drug Development Research. 2025. doi:10.1002/ddr.70037
BibTeX
@article{Bayoumi2025,
author = {Bayoumi, Hatem Hussein and Ibrahim, Mohamed-Kamal and Dahab, Mohammed A and Khedr, Fathalla and El-Adl, Khaled},
title = {Phthalazine Derivatives as VEGFR‐2 Inhibitors: Docking, ADMET, Synthesis, Design, Anticancer Evaluations, and Apoptosis Inducers},
journal = {Drug Development Research},
year = {2025},
doi = {10.1002/ddr.70037}
}
EUVIMED